

# FOCUS ON: HIV

## Working to Make HIV History

The Global Public Health organization at Johnson & Johnson is supporting global efforts to end HIV by expanding access to new treatment and prevention options, supporting community-based education and outreach efforts and accelerating R&D to meet the needs of people living with HIV everywhere.



### THE CHALLENGE

In 1981, the first cases of what would become known as AIDS were reported. Forty years later, HIV/AIDS remains one of the world's most significant health challenges. More than thirty-eight million people worldwide are living with HIV today and 1.5 million more acquired it in 2021.<sup>1</sup> Many of these people belong to underserved communities.

The world has made tremendous strides in combatting HIV, but millions of people lack access to treatment and prevention services. COVID-19 has worsened many of these challenges, making it even more difficult for many people living with HIV to access care.

### OUR RESPONSE

Johnson & Johnson has been engaged in the fight against HIV for nearly 40 years, and in that time, we've made tremendous progress, helping discover and develop HIV treatments, reshaping regimens and supporting people and communities on the front lines. But despite global progress, HIV remains one of the world's most pressing public health challenges.

Over the past few decades, we've introduced 9 HIV medicines, and our scientists are continuing to innovate to further empower people to manage their treatment. We're also committed to finding novel ways to prevent new cases of HIV.

We haven't wavered in our commitment to people living with HIV. We're working to increase global access to the latest HIV treatments that better fit patient needs, from the lab to the last mile – regardless of where in the world they are located.

We can't do it alone. We're collaborating with numerous organizations around the world on the goal of making HIV history through community-based prevention, testing and education initiatives in a determined effort to turn the tide of the epidemic.

Working together, we won't stop until we make HIV history.

### BY THE NUMBERS

How we're making an impact:

9

HIV medicines developed

100

HIV programs supported globally

3.5M+

Young women and girls supported with HIV prevention education through the DTAA program

3.1M+

Men in sub-Saharan Africa newly initiated into HIV treatment through the MenStar coalition


1. <https://www.unaids.org/en/resources/fact-sheet>

## INNOVATING IN THE LAB




### DAPIVIRINE RING

Developed by the International Partnership for Microbicides (IPM) under an exclusive license from Janssen, the WHO-recommended dapivirine vaginal ring is the world's first discreet, long-acting HIV prevention method designed for women. It has received Prequalification from the World Health Organization (WHO) and has been approved by the European Medicines Agency, the Medicines Control Authority of Zimbabwe and the South African Health Products Regulatory Authority. It is now included in the WHO's clinical guidelines as an HIV prevention choice for women.



### LONG-ACTING INJECTABLE TREATMENT REGIMEN

Johnson & Johnson collaborated with ViiV Healthcare to develop a first-of-its-kind, long-acting injectable (LAI) treatment regimen for HIV, comprised of Janssen's rilpivirine and ViiV Healthcare's cabotegravir. The regimen has received regulatory approvals from the European Commission, the U.S. Food and Drug Administration, the Australian Therapeutic Goods Administration and from Health Canada, with filings ongoing in sub-Saharan Africa in 2022.



### HIV VACCINE

Janssen is working to develop a vaccine for HIV, which is now being evaluated in a large-scale efficacy trial – Mosaico Phase 3 – in men who have sex with men (MSM) and transgender people in Europe, North America and South America. The investigational mosaic-based regimen is designed as a "global vaccine" with the goal to be deployed anywhere in the world and prevent a wide range of viral strains responsible for the HIV epidemic.





## STANDING WITH COMMUNITIES IN NEED



### DREAMS Thina Abantu Abasha

DREAMS Thina Abantu Abasha (DTAA) is a youth-led initiative aimed at reducing HIV acquisition rates among youth in South Africa. The program was launched in 2018 and is being implemented in two of the country's provinces with high rates of HIV: KwaZulu-Natal and Gauteng. This program is an evolution from DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe), an ambitious partnership led by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and supporting organizations, including Johnson & Johnson, to reduce acquisition of HIV among adolescent girls and young women (AGYW) in 10 sub-Saharan Africa countries.

In 2021, the DTAA program reached more than 1.3 million AGYW through a reading competition, targeted radio programming and extensive use of social media, and since 2018, the program has reached almost 4 million adolescent girls and young women.



### MenStar Coalition

In 2018, Johnson & Johnson – together with the Children's Investment Fund Foundation, the Elton John AIDS Foundation, Gilead Sciences, PEPFAR, The Global Fund to Fight AIDS, Tuberculosis and Malaria and Unitaid – launched the MenStar Coalition to address the unique needs of men in the HIV epidemic, particularly in sub-Saharan Africa. Since launching, the MenStar Coalition has brought more than 3.1 million more men into care with a 95 percent viral suppression rate. Johnson & Johnson is also proud to contribute our expertise on brand development, segmentation and human-centered communications to the development and launch of the MINA. FOR MEN. FOR HEALTH. campaign in South Africa, which focuses on the health and wellbeing of men, while also engaging them in HIV care.



### Collaborative Drone Program

In close collaboration with the local community and institutions, Johnson & Johnson is supporting a new, innovative program to use medical drones to deliver lifesaving HIV treatments quickly, efficiently and reliably to people in the remote island communities of Uganda's Kalangala District. The program serves more than 1,000 people living with HIV around the region and is gathering important data to inform future efforts aimed at scaling drone technology to solve other last mile delivery challenges, both in Uganda and beyond.

## IMPROVING HIV CARE FOR MOTHERS & CHILDREN



### mothers2mothers

With support from the Johnson & Johnson Foundation, the mothers2mothers (m2m) initiative employs, trains and helps to empower HIV-positive women as “Mentor Mothers” – community health workers who work in local communities and at understaffed health facilities to ensure that HIV-positive pregnant women and their families receive the health advice and medication they need.

By virtue of their position, Mentor Mothers become role models, putting a face on empowered, strong and healthy HIV-positive women and helping to reduce HIV-related stigma and discrimination. Johnson & Johnson has worked with m2m since 2006, reaching more than 1.3 million women in nine countries. Currently, program activities focus on supporting the role of Mentor Mothers as frontline health care workers who work to improve the overall health outcomes of families in Kenya, Uganda, Mozambique and South Africa.

### New Horizons Collaborative

The New Horizons Collaborative (NHC), launched by Johnson & Johnson, the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and other collaborators, works to provide children, adolescents and young people in need with second- and third-line treatment for HIV, which impacts approximately two million children worldwide. The initiative builds awareness, inspires action and advances learning using an integrated approach to improve and scale-up pediatric HIV care through medicine donations and healthcare system strengthening in 11 countries with high burdens of HIV infection.

## ABOUT J&J GLOBAL PUBLIC HEALTH

Through a dedicated global public health (GPH) organization that combines world-class research and development, global strategy, and external affairs capabilities and local implementation and impact teams, we put the world’s most underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformational products. Working with global and local partners, we ensure the critical solutions necessary are within reach of those who need them to save lives, cure patients, and prevent disease.

Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges and doing our part to close the gap of inequity and help pave the way to a healthier future where all people and communities can thrive.